Disc Medicine, Inc. (NASDAQ:IRON) Receives $104.44 Average Price Target from Analysts

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have earned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $104.4444.

A number of research firms have commented on IRON. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Wedbush reiterated an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Morgan Stanley raised their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, June 15th. Finally, Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th.

Insider Transactions at Disc Medicine

In other news, COO Jonathan Yen-Wen Yu sold 18,612 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $69.19, for a total value of $1,287,764.28. Following the completion of the sale, the chief operating officer owned 54,324 shares in the company, valued at $3,758,677.56. This represents a 25.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Rahul Khara sold 7,500 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $70.22, for a total value of $526,650.00. Following the transaction, the insider directly owned 52,173 shares of the company’s stock, valued at $3,663,588.06. This represents a 12.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 78,969 shares of company stock valued at $5,557,091. Company insiders own 3.76% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Several hedge funds and other institutional investors have recently bought and sold shares of IRON. Arizona State Retirement System lifted its holdings in Disc Medicine by 2.2% in the 4th quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock valued at $540,000 after acquiring an additional 144 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Disc Medicine by 3.3% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after purchasing an additional 215 shares during the last quarter. AlphaCentric Advisors LLC grew its stake in shares of Disc Medicine by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock worth $254,000 after purchasing an additional 216 shares during the last quarter. Avanza Fonder AB raised its holdings in shares of Disc Medicine by 14.1% in the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock worth $151,000 after purchasing an additional 235 shares in the last quarter. Finally, Kennedy Capital Management LLC raised its holdings in shares of Disc Medicine by 3.3% in the 4th quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock worth $740,000 after purchasing an additional 296 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Price Performance

Shares of NASDAQ IRON opened at $76.59 on Wednesday. Disc Medicine has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The firm’s 50-day simple moving average is $70.42 and its 200 day simple moving average is $70.03. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.92 billion, a P/E ratio of -11.57 and a beta of 0.97.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03). Equities analysts expect that Disc Medicine will post -6.74 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.